echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 1.5 billion injections!

    1.5 billion injections!

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 9, Haisco issued an announcement that its wholly-owned subsidiary, Liaoning Haisco Pharmaceuticals, had obtained approval for its supplementary application for the consistency evaluation of cefmetazole sodium for injection, making it the second company to review the product
    .


    Prior to this, Chengdu Better Pharmaceutical won the first review with a supplementary application


    Basic drug information

    Cefmetazole plays a bactericidal effect by inhibiting the cell wall synthesis of bacteria in the proliferation stage.
    It is a broad-spectrum cephalosporin antibiotic.
    It is highly stable to β-lactamase and is resistant to β-lactamase and non-β-lactamase production.
    Sensitive bacteria have the same strong antibacterial activity
    .

    According to data from Meinenet, the sales of cefmetazole sodium for terminal injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 1.
    5 billion yuan in 2020
    .


    Among them, Sichuan Hexin Pharmaceutical has the largest market share, exceeding 50%, and Shandong Luoxin Pharmaceutical Group and Harbin Pharmaceutical General Factory rank second and third


    Supplementary application for consistency evaluation of cefmetazole sodium for injection is under review

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    There are 27 manufacturers of cefmetazole sodium for injection, and only Chengdu Better Pharmaceuticals and Liaoning Haisco Pharmaceuticals have been approved for supplementary applications
    .


    At present, the product has the supplementary applications for consistency evaluation of Shandong Luoxin Pharmaceutical Group, Harbin Pharmaceutical General Factory, Sichuan Hexin Pharmaceutical, etc.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.